Pfizer, Alloy Therapeutics unite on new antibody discovery platform
Boston: Alloy Therapeutics Inc., a biotechnology ecosystem company has announced its latest strategic collaboration with Pfizer Inc., to develop a new platform.
The new platform could enhance Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.
Under the terms of the collaboration, Alloy will receive an upfront payment from Pfizer and will be eligible for pre-specified preclinical to commercial milestones on products originating from the newly developed platform.
“Pfizer has leveraged our industry-leading ATX-Gx platform for several years, and we collaborated closely with them to develop the common light chain ATX-CLC strains. This collaboration exemplifies how pharma can leverage Alloy’s technology and expertise broadly in antibody discovery and technological innovation by participating in the creation of pre-competitive tools,” said Heather Schwoebel, Chief Business Officer, Antibodies and Head of Strategic Collaborations at Alloy. “We will now apply this expertise to jointly create a new platform that enhances Pfizer’s ability to develop antibodies against challenging high-value targets. We are proud to expand our collaboration with Pfizer in the fight against disease.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.